{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(5)"],"submitter":["Aregui A"],"pubmed_abstract":["Walking speed (WS) has emerged as a potential predictor of mortality in elderly cancer patients, yet data involving non-small-cell lung cancer (NSCLC) patients are scarce. Our prospective exploratory study sought to determine whether WS would predict early death or toxicity in patients with advanced NSCLC receiving first-line systemic intravenous treatment. Overall, 145 patients of ≥70 years were diagnosed with NSCLC over 19 months, 91 of whom displayed locally-advanced or metastatic cancer. As first-line treatment, 21 (23%) patients received best supportive care, 13 (14%) targeted therapy, and 57 (63%) chemotherapy or immunotherapy. Among the latter, 38 consented to participate in the study (median age: 75 years). Median cumulative illness rating scale for geriatrics (CIRS-G) was 10 (IQR:"],"journal":["Cancers"],"pagination":["1344"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8909325"],"repository":["biostudies-literature"],"pubmed_title":["Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study."],"pmcid":["PMC8909325"],"pubmed_authors":["Pluvy J","Esnault H","Israel T","Khalil A","Aregui A","Raynaud Simon A","Guyard A","Meyer M","Gounant V","Zalcman G","Sanchez M"],"additional_accession":[]},"is_claimable":false,"name":"Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study.","description":"Walking speed (WS) has emerged as a potential predictor of mortality in elderly cancer patients, yet data involving non-small-cell lung cancer (NSCLC) patients are scarce. Our prospective exploratory study sought to determine whether WS would predict early death or toxicity in patients with advanced NSCLC receiving first-line systemic intravenous treatment. Overall, 145 patients of ≥70 years were diagnosed with NSCLC over 19 months, 91 of whom displayed locally-advanced or metastatic cancer. As first-line treatment, 21 (23%) patients received best supportive care, 13 (14%) targeted therapy, and 57 (63%) chemotherapy or immunotherapy. Among the latter, 38 consented to participate in the study (median age: 75 years). Median cumulative illness rating scale for geriatrics (CIRS-G) was 10 (IQR:","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-03T22:25:16.449Z","creation":"2024-10-15T21:40:29.788Z"},"accession":"S-EPMC8909325","cross_references":{"pubmed":["35267652"],"doi":["10.3390/cancers14051344"]}}